Syros Pharmaceuticals stock tracks its cash runway

By Christina Vaughn, Background & Management desk. Reviewed on July 7, 2026 at 7:33 p.m. ET.

Syros Pharmaceuticals (ISIN US8719201096) is a Nasdaq-listed biotechnology company whose shares remain tied to financing capacity, development milestones and broader small-cap biotech sentiment. The stock trades in the US market, giving investors a direct read on how the market prices clinical and balance-sheet risk.

Balance-sheet pressure

For development-stage biotech companies, cash runway and funding access often matter as much as pipeline news. That dynamic is especially relevant for Syros, because its business model depends on advancing programs before commercial revenue can support operations.

Pipeline focus

The company describes itself as a precision medicine biotech focused on gene control and cancer-related research. Its work has centered on drug candidates aimed at hard-to-treat hematology and oncology settings, a profile that makes every development update material for valuation.

Lead program profile

Syros has positioned its research around small-molecule approaches intended to modulate gene expression. That scientific strategy is central to the company's investment case because it determines both the size of the addressable market and the timing of data readouts.

Trading context

As of July 7, 2026, Syros Pharmaceuticals trades on Nasdaq in US dollars. The company's market value and share price can change quickly around clinical, financing or listing-related developments, which is typical for the segment.

This article was generated automatically and technically reviewed before publication. Market prices, analyst data and company information are provided without warranty and may change at short notice. This content is for informational purposes only and is not investment, financial, legal or tax advice. It is not a recommendation to buy or sell any security. Investing in securities involves risk, including the possible loss of principal.